Please assess the completion status of the following clinical trial:

Trial Title: Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ischemic stroke within 12 hours for the first time before entry into the study~* National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25~Exclusion Criteria:~* with lacunar infarction~* with cerebral hemorrhagic infarction~* with epilepsy or epileptic persons~* with history of neurological diseases~* with myocardial infarction,~* with renal and hepatic abnormalities~* with metabolic diseases~* with contraindications to antiplatelet treatments

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Dl-3-n-butylphthalide (Type: EXPERIMENTAL): Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
- Cerebrolysin (Type: EXPERIMENTAL): Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous infusion of 100 ml saline intravenous q.d. for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).